Carisma Therapeutics has increased its series B round to $59m thanks to an extension backed by IP Group, Penn Medicine and 4Bio Capital.

Penn Medicine contributed to a $12m extension for the cancer immunotherapy developer's series B round, which already inlcuded Livzon, Merck & Co and AbbVie.

Siemens' Next47 unit led a series B round for the email security platform developer, increasing its total funding to more than $46m.

GC and its GC LabCell subsidiary both contributed to a round that will help advance the cancer immunotherapy developer's NK cell drug pipeline.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The cybersecurity software developer will allocate the proceeds from the round to international growth and product development.

SIG affiliate Heights Capital Management was among the investors in a series B round for the small molecule therapeutics developer.

Returning investor Money Forward contributed to a $12.4m round led by venture firm East Ventures' growth fund.

Susquehanna International Group co-led a round that will allow the Tencent and Akatsuki-backed online maths education provider to expand its offering.

Motley Fool Ventures and ProMedica were among the investors in the tech apprenticeship provider’s latest round, which pushed its overall funding past $100m.